drugset / Trial / NCT00602680
Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of the study is to assess the effect of 3 doses of SSR180711C on cognitive performance in patients with mild Alzheimer's Disease (AD). Other objectives are to assess the safety/tolerability of SSR180711C in patients with mild AD.
Timeline
- Start
- 2008-01
- Primary completion
- 2008-07
- Completion
- 2008-07
Outcome
Outcome not reported
Stopped: “Insufficient expected benefit risk”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Donepezil | Small molecule | — | — |
| Subject | SSR180711C | Small molecule | — | — |